Ad
related to: dendreon stock newshugealerts.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting ...
While shares are up 16% to $5.96, this stock closed at $5.10 yesterday and that was the basis for the price being called a double to $10.00 and also the basis for the research call. Dendreon did ...
Craving more input? Start by adding Dendreon to your free and personalized watchlist so you can keep up on the latest news with the company. What's inside Supernova?
In this week's edition, the team talks about The Atlantic's fifth annual Health Care Forum, biotechs in the news, two stocks investors need to watch, and more.
The article Has Dendreon Become the Perfect Stock? originally appeared on Fool.com. Fool contributor Dan Caplinger doesn't own shares of the companies mentioned.
Down 35% in the last 12 months, the market has clearly been skeptical of biotech company Dendreon . Concerns over the market opportunity for its prostate cancer drug, Provenge, and question marks ...
Dendreon's score of 4 seems safely in the middle ground. But the bombshell that the biotech dropped on investors last week could spell disaster for the company's future.
No stock sums up biotech investing quite like Dendreon (NAS: DNDN) , the company behind a novel prostate cancer treatment called Provenge. In what amounts to a case study on unchecked optimism ...
Ad
related to: dendreon stock newshugealerts.com has been visited by 10K+ users in the past month